Incyte Corporation (INCY)
$108.62-2.46%Close
SELLBEAR · day 10
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $22.0B
- Beta
- 0.74
- P/E (TTM)
- 13.36
- Short % float
- 4.97%
- Days to cover
- 6.1
- SI change
- +0.1%
- 1W
- -3.65%
- 1M
- -11.11%
- vs SPY 1W
- -3.51%
- vs SPY 1M
- -13.61%
Industry peers
FMP comparable companies · ranked by market cap
- REGNSELLRegeneron Pharmaceuticals, Inc.$77.6BBEARQ 24$753.12-1.27%
- GMABBUYGenmab A/S$22.5BBULLQ 21$36.57-2.14%
- EXELBUYExelixis, Inc.$15.0BBULLQ 10$59.51-0.52%
- LGNDBUYLigand Pharmaceuticals Incorporated$6.1BRECOVERYQ 15$303.53-2.44%
- LEGNSELLLegend Biotech Corporation$3.3BRECOVERYQ 2$17.88+0.45%
- SLSSELLSELLAS Life Sciences Group, Inc.$2.3BRECOVERYQ -8$12.41+4.02%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.13-0.14%
- CGEMSELLCullinan Therapeutics, Inc.$867MCRISISQ 1$14.10-5.69%
- AVBPSELLArriVent BioPharma, Inc.$749MCRISISQ -6$16.09-2.25%
- VSTMBUYVerastem, Inc.$655MRECOVERYQ 4$7.45-9.70%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on INCY?
- LOPJLB’s latest quantitative signal on Incyte Corporation (INCY) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is INCY in?
- Incyte Corporation (INCY) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Incyte Corporation (INCY) do?
- Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inh…